MMRV Childhood Vaccine Study

Is your child between 4 and 6 years old?

Join our clinical research study that is aiming to offer a potential new vaccine option to help protect children from childhood illnesses.

Sign Up
Collage of diverse families smiling and hugging, with a blue shield symbolizing protection.
Child's shoulder and upper back with a red, blotchy rash on the skin surface of a young person’s shoulder area.

Why This Study Matters

Measles, mumps, rubella, and chickenpox (varicella) are all very contagious infections and can cause serious illness in children. Availability of more vaccines is important because vaccination helps to prevent infections and protect children from severe illness. The Twinkle-006 Study is looking at an investigational vaccine for the prevention of measles, mumps, rubella, and chickenpox in children. The study will evaluate the immune response produced by a dose of the study vaccine and will monitor how safe the study vaccine is. The study vaccine will be compared with a routine vaccine approved for the prevention of measles, mumps, rubella, and chickenpox. The comparator vaccine is already available for use in more than 90 countries.

Your child may be able to take part if they:

  • are 4–6 years of age
  • are in good health
  • have received a single (first) dose of a measles, mumps, rubella, and chickenpox vaccine in their second year of life
  • have not had measles, mumps, rubella, or chickenpox
A member of our research team will review additional eligibility requirements with you.
Man carrying a young boy on his shoulders outdoors in autumn with orange leaves in the background.
Nurse in blue scrubs smiling while talking with a patient and a child by a window, stethoscope visible.

What to Expect During the Study

Measles, mumps, rubella, and chickenpox (varicella) are all very contagious infections and can cause serious illness in children. Availability of more vaccines is important because vaccination helps to prevent infections and protect children from severe illness. The Twinkle-006 Study is looking at an investigational vaccine for the prevention of measles, mumps, rubella, and chickenpox in children. The study will evaluate the immune response produced by a dose of the study vaccine and will monitor how safe the study vaccine is. The study vaccine will be compared with a routine vaccine approved for the prevention of measles, mumps, rubella, and chickenpox. The comparator vaccine is already available for use in more than 90 countries.

Space is Limited.

Call Today at 972-354-1520 to Get Qualified.

Signing up is Easy by Following These 5 Simple Steps!

Please fill out the submission form provided below.

One of our friendly medical screeners will contact you.

The screener will organize a no-cost medical consultation and examination if you meet the eligibility criteria.

Your appointments will be scheduled, and you may receive study-related medication.

You may receive Compensation for your time and travel.

Sign Up

What else do I need to consider?

The study team will explain the possible benefits and risks of the study.

  • You do not have to allow your child to take part in the study if you do not want to.
  • If you choose for your child to take part in the study, they can stop participating at any time.
  • You and your child will not be paid to take part in this study, but you will be reimbursed for reasonable travel costs during your child’s participation.
  • The vaccine in the study and all study-related tests will be provided at no cost to you.
  • A team of doctors and nurses will monitor your child’s health carefully during the study.
  • The study has been reviewed by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC), which protects the rights, safety, and well-being of the participants.
Pediatric doctor uses a stethoscope to listen to a young boy's chest during a medical checkup.

What Are the Benefits of Participating?

Families who participate will receive:

  • Study-related vaccines at no cost
  • Study-related medical evaluations and laboratory testing at no cost
  • Care from experienced physicians and research professionals
  • Reimbursement for reasonable travel expenses
  • The opportunity to contribute to research that may benefit children in the future
While your child may or may not receive direct medical benefit, participation helps researchers continue improving vaccine options for future generations.

Your Child's Safety Comes First

Your child’s health and safety are the highest priorities throughout the study.

During participation:

  • Qualified physicians and nurses closely monitor your child's health
  • You may ask questions at any time
  • Participation is completely voluntary
  • You may withdraw your child from the study at any time without penalty
The study has been reviewed and approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC) to help protect the rights, safety, and well-being of study participants.
Gloved hand holding a small glass vial above a row of three vials on a lab bench.
Doctor in a white coat high-fives a smiling young girl seated on a couch, with her mother beside them in a bright room.

What Is a Clinical Research Study?

Clinical research studies help physicians and scientists evaluate investigational medications and vaccines before they become widely available.


These studies help answer important questions such as:

  • Is the vaccine safe?
  • Does it produce the desired immune response?
  • How does it compare with currently available vaccines?
  • Are there any side effects?

Every approved vaccine available today was studied through clinical research before becoming available to the public.

See if Your Child May Qualify

Together, let’s work towards increasing options to protect all our little ones from measles, mumps, rubella, and chickenpox. If your child is 4–6 years old and meets the study requirements, we invite you to learn more about the Twinkle-006 Study.

Complete the short form or contact ACRC Trials today to speak with a member of our research team.